SEOM clinical guidelines in Hereditary Breast and ovarian cancer

• G. Llort ^[1] ; I. Chirivella ^[2] ; R. Morales ^[8] ; R. Serrano ^[3] ; A. Beatriz Sanchez ^[4] ; A. Teulé ^[9] ; E. Lastra ^[5] ; J. Brunet ^[10] ; J. Balmaña ^[6] ; B. Graña ^[7]
  1. [1] Corporació Sanitària Parc Taulí

     Corporació Sanitària Parc Taulí

     Barcelona, España

     
  2. [2] Hospital Clinico Universitario de Valencia

     Hospital Clinico Universitario de Valencia

     Valencia, España

     
  3. [3] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  4. [4] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  5. [5] Complejo Asistencial Universitario de Burgos

     Complejo Asistencial Universitario de Burgos

     Burgos, España

     
  6. [6] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  7. [7] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  8. [8] Hospital La Mancha Centro
  9. [9] Institut Català d’Oncologia-IDIBELL
  10. [10] Institut Català d’Oncologia-IDIBGI

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 956-961
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Approximately, 7 % of all breast cancers (BC) and 11–15 % of ovarian cancers (OC) are associated with inherited predisposition, mainly related to germline mutations in high penetrance BRCA1/2 genes. Clinical criteria for genetic testing are based on personal and family history to estimate a minimum 10 % detection rate. Selection criteria are evolving according to new advances in this field and the clinical utility of genetic testing. Multiplex panel testing carries its own challenges and we recommend inclusion of genes with clinical utility. We recommend screening with annual mammography from age 30 and breast MRI from age 25 for BRCA1 and BRCA2 mutation carriers. Bilateral salpingo-oophorectomy should be offered to women with a BRCA1 or BRCA2 mutation, between 35 and 40 years and after completion of childbearing, or individualise based on the earliest age of ovarian cancer diagnosed in the family. Bilateral risk-reducing mastectomy is an option for healthy BRCA1 and BRCA2 mutation carriers, as well as contralateral mastectomy for young patients with a prior BC diagnosis. BRCA genetic testing in patients with BC and OC may influence their locoregional and systemic treatment.